Healthcare
Veru Inc.(VERU)
Live Price
Offline$2.95
-1.34% today
1Y Change
-51.61%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $40.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +61.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veru Inc. (VERU) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $2.95 and down 51.6% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +61.8%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +61.8%, free cash flow -37.6% with operating margin -8065.1% and ROIC -48.4%. Valuation already assumes a fairly strong business story at price/sales 146.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VERU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
-8065.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +61.8%, with operating margin around -8065.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.5% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.0% | +6.2% | +43.5% |
2026 Feb 11, 2026 | +44.7% | -2.6% | +8.3% | +7.0% |
2025 Dec 17, 2025 | -64.4% | +1.3% | +4.9% | +14.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VERU
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VERU Max Drawdown
-70.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VERU and SPY.
Company Overview
Veru Inc.
NASDAQ Capital Market
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
- Leadership
- Mitchell S. Steiner
- IPO Date
- Feb 11, 1999
- Employees
- 210
- Street Address
- 48 NW 25th Street
- Mailing
- Miami, FL, 33127
- Region
- Miami, FL, US
- Reporting Currency
- USD
- Investor Line
- 305 509 6897
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 146.8
- Price/Book
- 1.2
Growth
- Revenue
- -100.0%
- EPS
- +61.8%
- Free Cash Flow
- -37.6%
Profitability
- Gross Margin
- -46.7%
- Operating Margin
- -8065.1%
- Net Margin
- -7736.3%
- ROE
- -83.2%
- ROIC
- -48.4%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 5.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.